Halozyme Therapeutics | HALO - Current Liabilities


Halozyme Therapeutics reported $177.09M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Baxter International USD 2.97B 805M Dec/2025
Cara Therapeutics USD 10.68M 9.48M Jun/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
DBV Technologies USD 49.48M 60K Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
MannKind USD 109.13M 2.7M Sep/2025
Minerva Neurosciences USD 2.67M 143K Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025